Firefly Neuroscience

Firefly Neuroscience creates software and devices that help doctors assess brain health. Its tools support diagnosis and treatment for mental and neurological conditions. Hospitals and drug companies use these products to improve patient care and research.

Brainwaves and Beyond: What Firefly Sells

• Brain Network Analytics: Software that uses artificial intelligence to analyze brain activity for diagnosing mental and cognitive disorders. Main users are doctors and researchers.
• Evox System: Hardware and software package for recording and displaying brain electrical signals. Used in clinics and research settings.
• Service and Support: Ongoing technical help and training for healthcare providers and research clients.
• Equipment Rentals: Short-term access to brain assessment devices for clinics and studies.
• Custom Projects: Specialized work for pharmaceutical companies, including support for drug trials and clinical research.

Growth Spurts: How Firefly Has Evolved

• Acquired Evoke Neuroscience in April 2025, expanding product range and customer base.
• Raised $2.56 million net of issuance costs through equity offerings in March and June 2025.
• Integrated new hardware and software from Evoke Neuroscience into its main product line in 2025.
• Expanded operations in North America, with subsidiaries in the U.S. and Israel as of 2025.

Why Firefly Is a Bit Different

Firefly combines artificial intelligence with a large clinical database to offer objective brain health assessments. Its products are cleared by U.S. regulators, making them suitable for both clinical and research use. The company targets both healthcare providers and pharmaceutical firms with flexible pricing models.

Five Things You Need to Know

• Q2 2025 revenue was $299,000, up from $10,000 in Q2 2024.
• Net loss for Q2 2025 was $1.83 million, up from $1.26 million in Q2 2024.
• Cash balance was $5.92 million as of June 30, 2025, up from $1.81 million at year-end 2024.
• Operating loss for Q2 2025 was $1.63 million, compared to $1.26 million in Q2 2024.
• Company had 13 full-time employees and a market cap of $22.09 million as of June 2025.

Bottom Line

Firefly has expanded its product line and customer base through acquisition and integration. The company faces ongoing financial challenges but continues to focus on brain health technology for clinical and research markets.